- Home
- PAM vs KRYS Comparison
PAM vs KRYS Comparison
Compare PAM & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAM
- KRYS
- Stock Information
- Founded
- PAM 1945
- KRYS 2015
- Country
- PAM Argentina
- KRYS United States
- Employees
- PAM N/A
- KRYS N/A
- Industry
- PAM Electric Utilities: Central
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAM Utilities
- KRYS Health Care
- Exchange
- PAM Nasdaq
- KRYS Nasdaq
- Market Cap
- PAM 3.8B
- KRYS 4.3B
- IPO Year
- PAM N/A
- KRYS 2017
- Fundamental
- Price
- PAM $67.53
- KRYS $147.70
- Analyst Decision
- PAM Buy
- KRYS Strong Buy
- Analyst Count
- PAM 3
- KRYS 10
- Target Price
- PAM $85.83
- KRYS $204.90
- AVG Volume (30 Days)
- PAM 273.4K
- KRYS 393.6K
- Earning Date
- PAM 08-06-2025
- KRYS 08-04-2025
- Dividend Yield
- PAM N/A
- KRYS N/A
- EPS Growth
- PAM N/A
- KRYS 36.22
- EPS
- PAM 0.33
- KRYS 4.91
- Revenue
- PAM $1,875,000,000.00
- KRYS $359,205,000.00
- Revenue This Year
- PAM $135,871.60
- KRYS $34.33
- Revenue Next Year
- PAM $26.02
- KRYS $47.84
- P/E Ratio
- PAM $8.49
- KRYS $30.11
- Revenue Growth
- PAM N/A
- KRYS 116.08
- 52 Week Low
- PAM $51.76
- KRYS $122.80
- 52 Week High
- PAM $97.55
- KRYS $207.84
- Technical
- Relative Strength Index (RSI)
- PAM 39.74
- KRYS 51.88
- Support Level
- PAM $65.38
- KRYS $143.09
- Resistance Level
- PAM $71.14
- KRYS $151.86
- Average True Range (ATR)
- PAM 3.13
- KRYS 4.51
- MACD
- PAM -0.82
- KRYS 0.32
- Stochastic Oscillator
- PAM 16.09
- KRYS 69.24
About PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.